TY - JOUR
T1 - Turning tumour cells into antigen presenting cells
T2 - The next step to improve cancer immunotherapy?
AU - de Charette, Marie
AU - Marabelle, Aurélien
AU - Houot, Roch
N1 - Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Downregulation/loss of the antigen presentation is a major immune escape mechanism in cancer. It allows tumour cells to become ‘invisible’ and avoid immune attack by antitumour T cells. In tumour harbouring properties of professional antigen presenting cells (i.e. tumour B cells in lymphoma), downregulation/loss of the antigen presentation may also prevent direct priming of naïve T cells by tumour cells. Here, we review treatments that may induce/restore antigen presentation by the tumour cells. These treatments may increase the generation of antitumour T cells and/or their capacity to recognise and eliminate tumour cells. By forcing tumour cells to present their antigens, these treatments may sensitise patients to T cell–based immunotherapies, including checkpoint inhibitors.
AB - Downregulation/loss of the antigen presentation is a major immune escape mechanism in cancer. It allows tumour cells to become ‘invisible’ and avoid immune attack by antitumour T cells. In tumour harbouring properties of professional antigen presenting cells (i.e. tumour B cells in lymphoma), downregulation/loss of the antigen presentation may also prevent direct priming of naïve T cells by tumour cells. Here, we review treatments that may induce/restore antigen presentation by the tumour cells. These treatments may increase the generation of antitumour T cells and/or their capacity to recognise and eliminate tumour cells. By forcing tumour cells to present their antigens, these treatments may sensitise patients to T cell–based immunotherapies, including checkpoint inhibitors.
KW - Antigen presentation
KW - Cancer
KW - Checkpoint inhibitors
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=84991711222&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2016.09.010
DO - 10.1016/j.ejca.2016.09.010
M3 - Review article
C2 - 27755997
AN - SCOPUS:84991711222
SN - 0959-8049
VL - 68
SP - 134
EP - 147
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -